Search results
Showing 61 to 75 of 132 results for myeloma
the life-extending benefits of lenalidomide when used in people with multiple myeloma who have received two or more prior therapies. Any...
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
NICE's past research and projects
Find out what guidance is being considered for development
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
Past technology appraisal appeals and decisions
fluorescence in-situ hybridisation (FISH), in people with newly diagnosed myeloma who are starting treatment? Any explanatory notes(if...
Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.
View recommendations for HTG3Show all sections
Sections for HTG3
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]
Awaiting development Reference number: GID-TA11661 Expected publication date: TBC
Awaiting development Reference number: GID-TA11052 Expected publication date: TBC
performed before thalidomide, bortezomib and lenalidomide were used as myeloma treatments.These drugs produce better responses and also...
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
Awaiting development Reference number: GID-TA11162 Expected publication date: 28 July 2027